Categories
- Global News Feed
- Uncategorized
- Alabama Stem Cells
- Alaska Stem Cells
- Arkansas Stem Cells
- Arizona Stem Cells
- California Stem Cells
- Colorado Stem Cells
- Connecticut Stem Cells
- Delaware Stem Cells
- Florida Stem Cells
- Georgia Stem Cells
- Hawaii Stem Cells
- Idaho Stem Cells
- Illinois Stem Cells
- Indiana Stem Cells
- Iowa Stem Cells
- Kansas Stem Cells
- Kentucky Stem Cells
- Louisiana Stem Cells
- Maine Stem Cells
- Maryland Stem Cells
- Massachusetts Stem Cells
- Michigan Stem Cells
- Minnesota Stem Cells
- Mississippi Stem Cells
- Missouri Stem Cells
- Montana Stem Cells
- Nebraska Stem Cells
- New Hampshire Stem Cells
- New Jersey Stem Cells
- New Mexico Stem Cells
- New York Stem Cells
- Nevada Stem Cells
- North Carolina Stem Cells
- North Dakota Stem Cells
- Oklahoma Stem Cells
- Ohio Stem Cells
- Oregon Stem Cells
- Pennsylvania Stem Cells
- Rhode Island Stem Cells
- South Carolina Stem Cells
- South Dakota Stem Cells
- Tennessee Stem Cells
- Texas Stem Cells
- Utah Stem Cells
- Vermont Stem Cells
- Virginia Stem Cells
- Washington Stem Cells
- West Virginia Stem Cells
- Wisconsin Stem Cells
- Wyoming Stem Cells
- Biotechnology
- Cell Medicine
- Cell Therapy
- Diabetes
- Epigenetics
- Gene therapy
- Genetics
- Genetic Engineering
- Genetic medicine
- HCG Diet
- Hormone Replacement Therapy
- Human Genetics
- Integrative Medicine
- Molecular Genetics
- Molecular Medicine
- Nano medicine
- Preventative Medicine
- Regenerative Medicine
- Stem Cells
- Stell Cell Genetics
- Stem Cell Research
- Stem Cell Treatments
- Stem Cell Therapy
- Stem Cell Videos
- Testosterone Replacement Therapy
- Testosterone Shots
- Transhumanism
- Transhumanist
Archives
Recommended Sites
Category Archives: Global News Feed
Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand
Posted: January 2, 2025 at 2:44 am
TUSTIN, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the expiration of the waiting period under the Hart-Scott-Rodino (“HSR”) Antitrust Improvements Act of 1976 with respect to the previously announced agreement for Avid to be acquired by GHO Capital Partners LLP ("GHO") and Ampersand Capital Partners (“Ampersand”).
Posted in Global News Feed
Comments Off on Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand
2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025
Posted: January 2, 2025 at 2:44 am
DALLAS, Dec. 30, 2024 (GLOBE NEWSWIRE) -- The 2024 Rising Stars of the life sciences and healthcare innovation sector took center stage at the iC³ Life Science Summit this year, marking another milestone in recognizing groundbreaking achievements and emerging leaders in the field. The Rising Star recognition program, a cornerstone of the iC³ Summit, continues to identify, honor, and elevate promising innovators who are driving meaningful progress in biotech, healthcare, and life sciences industries.
More here:
2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025
Posted in Global News Feed
Comments Off on 2024 Rising Stars Shine at iC³ Summit: Celebrating Progress and Setting the Stage for 2025
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of…
Posted: January 2, 2025 at 2:44 am
Scilex notified NASDAQ on December 30, 2024 that it has set a new record date of January 28, 2025 (the “Record Date”) for the dividend of Scilex preferred stock to Scilex’s stockholders and certain other securityholders of Scilex. Scilex notified NASDAQ on December 30, 2024 that it has set a new record date of January 28, 2025 (the “Record Date”) for the dividend of Scilex preferred stock to Scilex’s stockholders and certain other securityholders of Scilex.
Follow this link:
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of...
Posted in Global News Feed
Comments Off on Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of…
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
Posted: January 2, 2025 at 2:44 am
Current Renovaro Chairman to Lead Subsidiary’s Development Program and Commercialization
Read the rest here:
Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
Posted in Global News Feed
Comments Off on Renovaro Inc. Appoints Maurice van Tilburg to Lead GEDi Cube BV
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
Posted: January 2, 2025 at 2:44 am
MELBOURNE, Australia and BRUSSELS, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX; Nasdaq: TLX, Telix, the Company) and the Brussels-based Oncidium foundation today announce that results for the NOBLE Registry of TLX599-CDx (99mTc-iPSMA) have been published in the European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI) Reports.
The rest is here:
NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
Posted in Global News Feed
Comments Off on NOBLE Registry Update: TLX599-CDx PSMA SPECT Imaging of Prostate Cancer Published in EJNMMI Reports
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million
Posted: January 2, 2025 at 2:44 am
WEST LAFAYETTE, Ind., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it had raised an additional $3.6 million in net proceeds from the optional shares in connection with its previously announced underwritten public offering of common shares. The Company issued the additional 900,000 shares at a price to the public of $4.25 per share. All the shares were offered and sold by the Company. The Company closed on the sale of the 900,000 optional shares of common stock on December 30, 2024.
Continue reading here:
Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million
Posted in Global News Feed
Comments Off on Inotiv, Inc. Completes Equity Offering for Net Proceeds of Approximately $3.6 Million
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Posted: January 2, 2025 at 2:44 am
PRINCETON, N.J., Dec. 30, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or the “Company”) (Nasdaq: ANIP) today announced that Nikhil Lalwani, President and Chief Executive Officer; Stephen Carey, Chief Financial Officer; and Dr. Mary Pao, Chief Medical Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025, at 2:15pm PST/5:15pm EST, in San Francisco.
More here:
ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Posted in Global News Feed
Comments Off on ANI Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering
Posted: January 2, 2025 at 2:44 am
Wuxi, China, Dec. 30, 2024 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (Nasdaq: PHH) (the “Company”), a company focused on developing private skincare labels, direct skincare product sales, and franchise alliance promotions, today announced the closing of its initial public offering (the “Offering”) of 1,200,000 ordinary shares (the “Ordinary Shares”) at a public offering price of $4.00 per ordinary share. The Ordinary Shares began trading on the Nasdaq Capital Market on December 27, 2024 under the ticker symbol “PHH.”
Visit link:
Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering
Posted in Global News Feed
Comments Off on Park Ha Biological Technology Co., Ltd. Announces Closing of $4.8 Million Initial Public Offering
Burning Rock Announces Results of 2024 Annual General Meeting
Posted: January 2, 2025 at 2:44 am
GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company’s 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions:
Follow this link:
Burning Rock Announces Results of 2024 Annual General Meeting
Posted in Global News Feed
Comments Off on Burning Rock Announces Results of 2024 Annual General Meeting
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
Posted: January 2, 2025 at 2:44 am
Galera’s development strategy shifts from toxicity reduction to anti-cancer therapeutics, with three trials in patients with highly resistant subsets of advanced breast cancer.
Visit link:
Galera Therapeutics completes acquisition of Nova Pharmaceuticals
Posted in Global News Feed
Comments Off on Galera Therapeutics completes acquisition of Nova Pharmaceuticals
